David is Professor of Health Informatics at Swansea University’s Medical School, where he is Deputy Director of Farr-CIPHER – one of the four UK Centres of Excellence for E-Health Research, funded by a consortium of top UK research funders led by the MRC, as part of the Farr Institute. He is also Principal investigator and Director of the Administrative Data Research Centre Wales (ADRCW), an £8million investment into Wales by the ESRC as part of its Big Data initiative.
David is joint lead of the SAIL Databank, an internationally recognised data linkage resource that safely and securely share linked and carefully de-identified data from a wide variety of routinely collected data from across Wales, and which supports a wide range of researchers from across the UK and internationally.
David is Director of the eHealth Industries Innovation (ehi2) Centre, developing links between academia, the NHS, and business within the UK and internationally. He is also University Director of NHS Wales Informatics Research Laboratories, created through a collaboration between Swansea University and NHS Wales Informatics Service, the national programme for NHS IT for Wales. David is a Fellow of the Royal Society for the Encouragement of the Arts, Manufactures and Commerce (FRSA) and past Chairman and a current Director of MediWales, a membership organisation representing the medical technology sector of Wales. He is a member of numerous committees and national bodies relating to health informatics and health-related research. He has received research grants and consultancy contracts valuing over £45m over recent years.
Duncan is an academic human geneticist. The primary aim of his laboratory is to examine the role that telomere dysfunction plays in driving genomic instability, clonal evolution and tumour progression. He has worked on human telomeres since 1992, starting with PhD and postdoctoral training with Dr. Nicola Royle and Professor Sir Alec Jeffreys at the University of Leicester. During this time they studied telomeric variation and mutation within the human population and the evolution of telomeric sequences within the great ape species. In 1999 he moved to the University of Wales at Cardiff Medical School (later part of Cardiff University) to develop his own independent research group. He obtained independent fellowship funding, firstly from Research into Ageing and later a senior fellowship from Cancer Research UK. In addition he has also received funding from the Leukaemia and Lymphoma Research, the Association for International Cancer Research, Cancer Research Wales and National Institute for Social Care and Health Research. Following the senior fellowship he became a member of staff at Cardiff University.
One of his lab’s key contributions to the telomere field has been the development of single telomere length analysis (STELA), a technique that determines telomere length from single DNA molecules from specific chromosome ends; this is the highest resolution approach for the estimation of telomere length and importantly detects the presence of short telomeres within the length ranges at which telomere dysfunction and fusion occurs. They have also developed the ability to detect and characterise telomere fusion events at the single molecule level. They have been using these tools to understand the mechanisms of telomere erosion, mutation and fusion, as well as undertaking translational work to examine the role of telomere dysfunction in tumour progression and to test the utility of telomere based prognostic markers.
James is co-lead of the work package for Trials through to Practice for the Wales Cancer Research Centre. James is Consultant Clinical Oncologist specialising in Neuro-Oncology and Lung cancer based at Velindre Cancer Centre, Cardiff. He completed a PhD at Cardiff University Institute of Cancer Genetics in 2014. His research interest is in Neuro-Oncology, in particular investigating novel imaging methods in adults with brain tumours. He has led the first Oncology research collaboration with the Cardiff University Brain Research Imaging Centre (CUBRIC) in Cardiff using technical MRI to investigate the effects of radiotherapy on cognitive function in patients with secondary brain tumours. He is also interested in developing technical radiotherapy for adults with Glioma and in studying how advanced MRI methods may be used in radiotherapy planning for brain tumours.
He is the clinical and research lead in Neuro-Oncology at Velindre Cancer Centre and is a member of the Glioma subgroup of the National Cancer Research Institute (NCRI) Brain Clinical Studies Group. He has developed clinical trial activity in Cardiff, improving access to clinical trials for patients with brain tumours in Wales. He is the lead local investigator for several brain tumour trials and sits on the trial management group of national trials in Neuro-Oncology.
Jim has a background of working in education and social services. In 2007 he joined the Involving People Advisory Group as a volunteer. In his voluntary career he has been involved in the Wales Cancer Trials Unit (WCTU) and Marie Curie Palliative Care Research Centre (MCPCRC)Trial Management and Study Groups. From from 2011 – 2014 he acted as Marie Curie's and WCTU’s Research Partner Coordinator.
He is an active contributor to Public Health Wales and Health & Care Research Wales. In 2015 he was made an Honorary Research Associate at Cardiff University’s School of Cancer and Genetics.
Jim has also worked on projects with Tenovous, Velindre NHS Trust and the Welsh Government. He plays a key role in the involvement of patients and the public in the Centre’s work.
Jodie Bond is a communications professional with a background working in research, the arts, the third sector and education. She joined the Wales Cancer Research Centre in 2015 when the organisation was in its infancy and has developed the Centre’s engagement activity, brand and reputation from scratch.
Jodie believes that through tailoring communications and engagement activities, we can help the public develop a greater understanding and appreciation of research and its impact on society. She knows how to catch the public’s interest, promote sell-out events, and influence stakeholders — and it’s not just keeping up to date with the latest developments on social media. It’s how much you value, and how well you connect with, the individuals you’re reaching out to.
Jodie has managed a number of successful communications and marketing campaigns. She has promoted sell-out international tours for the UK’s leading contemporary circus, managed multi-regional PR campaigns for the UK’s second largest charity, and worked as part of a team who won gold at the CIPR Cyrmu awards.
She holds a degree in Creative Writing and Video Production from Buckinghamshire New University.
Dr John Staffurth is a Reader in Oncology at the Institute of Cancer Genetics, Cardiff University and a Consultant Clinical Oncologist specialising in bladder and prostate cancer based at Velindre Cancer Centre in Cardiff, Wales.
His main research interests are technical radiotherapy for bladder and prostate cancer and the management of castrate refractory prostate cancer. He is a member of the National Cancer Research Institute (NCRI) Prostate Clinical Studies Group and is member of the Executive Group of the national radiotherapy research group CTRad. These are involved in the design and delivery of trials in both prostate cancer and radiotherapy. He is leading a Movember-funded research programme in pelvic radiotherapy survivorship as part of their True NTH initiative.
He has been the lead local investigator for multiple trials in both bladder and prostate cancer, and recruits to many other trials led by his colleagues in Cardiff and Velindre. He also sits on the Trial Management Groups and Independent Data Monitoring Committees of several trials across the spectrum of prostate cancer, bladder cancer and radiotherapy research.
Julie retired from her post as Deputy Director of Cardiff University Careers Service in December 2013, having spent 26 years in this field. Prior work experience included science teaching in secondary and further education and a period of three years early in her career in hospital management.
Her degree was in Physiology and Biochemistry and she has always been interested in health, health related research and the NHS. Some experiences of ill health in recent years meant that Julie became a frequent user of the NHS, which in turn meant that she had something to offer the Involving People Network, by feeding in the patient viewpoint to clinical research. She is currently a member of four Trial Management Teams for research projects, two Steering Groups, an All Wales Research Funding Prioritisation Panel (AWPP), and a NICE Committee on Diagnostic Services.
She hopes that my previous and current experiences will be an excellent background to enable me, as a member of the public, to contribute effectively as a Theme Research Partner for the Wales Cancer Research Centre.
Kate is a Health Psychologist based in the Division of Population Medicine at Cardiff University, leading research into psychosocial and behavioural aspects of cancer early detection. Her research expertise involves understanding the determinants of late symptom presentation and non-uptake of cancer screening, psychosocial outcomes of cancer screening in higher risk groups (including genetically defined groups), and developing and evaluating complex behavioural interventions designed to improve outcomes at each stage of the patient pathway, with a particular focus on reducing inequalities in cancer outcomes. She is academic lead for Wales in the International Cancer Benchmarking Partnership cancer awareness work, and leads a programme of research in cancer screening, prevention and early detection that bridges PRIME Centre Wales and the Wales Cancer Research Centre.